A drug that targets beta amyloid has slowed cognitive and functional decline

According to the results of a small, mid-stage clinical trial, it found a drug that targets beta amyloid has slowed cognitive and functional decline in people with early Alzheimer’s disease. In Eli Lilly’s drug trial, the participants taking the drug for about 76 weeks showed 32 percent slower decline in thinking and daily function measures when compared with those in a placebo group. Read article here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org